Key Responsibilities of a Marketing Authorization Holder Under EU Regulations
Summary:
- MAHs are responsible for product quality, safety, and efficacy throughout the product lifecycle.
- GMP compliance and quality oversight must be maintained, even when activities are outsourced.
- Pharmacovigilance activities include ADR reporting, safety monitoring, risk management, and PSMF maintenance.
- Regulatory compliance requires timely reporting, data integrity, and risk evaluation.
- Lifecycle management includes handling product variations and post-authorization changes.
- Continuous benefit-risk monitoring helps ensure patient safety.
A marketing authorization holder (MAH) plays a critical role in ensuring that medicinal products marketed in the European Union (EU) continue to meet Regulatory standards for quality, safety, and efficacy throughout their lifecycle. Beyond obtaining marketing approval, MAHs are responsible for maintaining good manufacturing practice (GMP) compliance, conducting Pharmacovigilance activities, managing regulatory reporting obligations, and implementing post-authorization changes.
Introduction
A marketing authorization holder (MAH) is the legal entity authorized to place a Medicinal product on the European Union (EU) market. Once a marketing authorization is granted, the MAH becomes responsible for ensuring that the medicine remains safe, effective, and of high quality throughout its lifecycle.1
The European Medicines Agency (EMA) and EU Pharmaceutical legislation place extensive obligations on MAHs that extend far beyond the initial approval of a medicine. These responsibilities encompass pharmacovigilance, quality management, Regulatory compliance, product data maintenance, and medicinal product lifecycle management.3
Understanding the Role of the MAH
In the EU, the MAH is the company or legal entity that holds authorization to market a medicinal product in one or more Member States. The MAH is legally accountable for ensuring compliance with all applicable EU regulations, regardless of whether certain activities are outsourced to third parties such as manufacturers, contract research organisations, or pharmacovigilance service providers. The responsibility for the product ultimately remains with the MAH.4
Ensuring Product Quality and Good Manufacturing Practice Compliance
One of the primary responsibilities of an MAH is ensuring that medicinal products are consistently manufactured and controlled according to approved quality standards. The MAH must establish and maintain an effective pharmaceutical quality system that guarantees compliance with good manufacturing practice (GMP) requirements.
Although manufacturing activities are frequently outsourced, EMA guidance emphasises that the MAH retains oversight responsibility. The MAH must also ensure that the product continues to comply with the approved marketing authorization dossier.
Quality oversight further includes management of product complaints, deviations, recalls, and supply chain integrity. Any issue that could affect product quality must be promptly evaluated and reported to the relevant authorities when required.4
Pharmacovigilance and Drug Safety Monitoring
“Pharmacovigilance is among the most significant responsibilities of an MAH in the EU.”
The EU legislation requires MAHs to monitor the safety profile of their products continuously after commercialisation. This obligation ensures that emerging risks are identified, assessed, and managed appropriately.
To fulfil these requirements, MAHs must establish and maintain a pharmacovigilance system master file (PSMF) and appoint a qualified person responsible for pharmacovigilance. The MAH must collect, evaluate, and report adverse drug reaction (ADR) information from healthcare professionals, patients, scientific literature, and other relevant sources in accordance with EU pharmacovigilance requirements.
Periodic safety update reports (PSURs), risk evaluations, and implementation of risk management plans are integral components of Pharmacovigilance obligations. When new safety concerns emerge, the MAH must take appropriate actions, which may include updating product information, conducting post-authorization safety studies, or implementing additional risk minimisation measures.5
Maintaining Regulatory Compliance
Effective compliance management requires MAHs to implement quality systems and processes that ensure continuous safety surveillance, accurate reporting, data integrity, and timely regulatory communication (Table 1).2,6
| Compliance Area | MAH Responsibility |
| Continuous Safety Monitoring | Continuously monitor pharmacovigilance data, evaluate risk minimisation options, and implement appropriate measures to protect patient safety. |
| Scientific Evaluation of Risks | Assess all available safety information, including adverse reactions occurring within or outside approved indications and those associated with occupational exposure. |
| Timely ADR Reporting | Submit accurate, complete, and verifiable adverse drug reaction (ADR) reports to regulatory authorities within the legally required timelines. |
| Data Quality and Integrity | Ensure the quality, completeness, and integrity of safety data, prevent duplicate submissions, and validate safety signals. |
| Regulatory Communication | Maintain effective communication with regulatory authorities regarding emerging risks, safety reports, risk management activities, and corrective actions. |
Table 1
Lifecycle Management and Variations
The responsibilities of an MAH continue long after initial approval. Any modification to a medicinal product (including changes in manufacturing processes, formulations, packaging, labelling, or indications) must be managed through established EU variation procedures.
MAHs are required to submit appropriate regulatory applications and obtain approval where necessary before implementing significant changes. This lifecycle management approach ensures that product quality, safety, and efficacy remain consistent throughout the product’s commercial existence.
In addition, MAHs must notify regulatory authorities regarding product withdrawals, suspensions, shortages, or other significant market-related developments that could affect patient access or safety.7
Conditional Marketing Authorization
For medicines approved through the EU’s conditional marketing authorization pathway, MAHs have additional obligations, including completing post-authorization studies, generating further clinical data, and demonstrating a continued positive benefit-risk balance. These authorizations are renewed annually until all specific obligations are fulfilled.8
Conclusion
The role of an MAH under EU regulations extends far beyond obtaining approval for a medicinal product. MAHs are responsible for maintaining product quality, safety, efficacy, and regulatory compliance throughout the Medicinal product lifecycle management. It mainly includes GMP oversight, Pharmacovigilance obligations, management of post-authorization changes, regulatory reporting, and continuous monitoring of the product’s benefit-risk balance. By fulfilling these EMA requirements, MAHs play a central role in protecting public health and maintaining confidence in the EU pharmaceutical regulatory framework.
References
1. Marketing authorisation holder | European Medicines Agency (EMA). Accessed June 9, 2026. https://www.ema.europa.eu/en/glossary-terms/marketing-authorisation-holder
2. Compliance: marketing authorisation | European Medicines Agency (EMA). March 31, 2017. Accessed June 9, 2026. https://www.ema.europa.eu/en/compliance-marketing-authorisation
3. Li J. Can the Marketing Authorisation Holder system improve the ESG performance of pharmaceutical manufacturers? Front Public Health. 2025;13:1587028. doi:10.3389/fpubh.2025.1587028
4. Reflection Paper on Good Manufacturing Practice and Marketing Authorisation Holders | European Medicines Agency (EMA). January 10, 2022. Accessed June 9, 2026. https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-good-manufacturing-practice-marketing-authorisation-holders_en.pdf
5. Mammì M, Citraro R, Torcasio G, Cusato G, Palleria C, di Paola ED. Pharmacovigilance in pharmaceutical companies: An overview. J Pharmacol Pharmacother. 2013;4(Suppl1):S33-S37. doi:10.4103/0976-500X.120945
6. PV_Guidance_Docs_for_MAH_Version_2_as_on_18.01.2024.pdf. Accessed June 9, 2026. https://www.ipc.gov.in/images/PV_Guidance_Docs_for_MAH_Version_2_as_on_18.01.2024.pdf
7. CHAPTER 1 MARKETING AUTHORISATION | EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. Accessed June 9, 2026. https://health.ec.europa.eu/system/files/2019-07/vol2a_chap1_en_0.pdf
8. Conditional marketing authorisation | European Medicines Agency (EMA). February 15, 2016. Accessed June 9, 2026. https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/conditional-marketing-authorisation
Recent Posts
Technical Documentation Requirements Under EU MDR and IVDR
Technical documentation is a fundamental requirement under the European Union Medical Device Regulation (EU MDR 2017/745) and In Vitro Diagnostic Medical Device Regulation (EU IVDR 2017/746). It provi..
Step-by-Step CE Marking Process for Medical Devices in the EU
CE Marking is a mandatory regulatory requirement for Medical Devices marketed in the European Union (EU) and European Economic Area (EEA). It confirms that a device meets necessary safety standards, h..
Contact us
Please feel free to talk to us if you have any questions. We endeavour to answer within 24 hours.